Curevac Nv Stock Performance
| CVAC Stock | USD 2.56 0.07 2.81% |
The firm shows a Beta (market volatility) of 1.11, which signifies a somewhat significant risk relative to the market. CureVac NV returns are very sensitive to returns on the market. As the market goes up or down, CureVac NV is expected to follow. At this point, CureVac NV has a negative expected return of -0.39%. Please make sure to confirm CureVac NV's maximum drawdown, kurtosis, day median price, as well as the relationship between the potential upside and daily balance of power , to decide if CureVac NV performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CureVac NV has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.99 | Five Day Return (5.47) | Year To Date Return (39.99) | Ten Year Return (95.50) | All Time Return (95.50) |
1 | CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress | 09/09/2024 |
2 | CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program | 09/12/2024 |
3 | CureVac N.V.s Share Price Could Signal Some Risk | 09/16/2024 |
4 | Contrasting CureVac and Innovation Pharmaceuticals | 10/08/2024 |
5 | CureVac names former Cardior CFO Axel Sven Malkomes as new CFO | 11/04/2024 |
6 | CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update | 11/12/2024 |
7 | A white couple donated 80 acres in an act of reparations. Now its becoming a home for Black farmers. | 11/14/2024 |
8 | Is the Options Market Predicting a Spike in CureVac Stock | 11/20/2024 |
| Begin Period Cash Flow | 495.8 M |
CureVac |
CureVac NV Relative Risk vs. Return Landscape
If you would invest 337.00 in CureVac NV on August 24, 2024 and sell it today you would lose (81.00) from holding CureVac NV or give up 24.04% of portfolio value over 90 days. CureVac NV is currently does not generate positive expected returns and assumes 3.1264% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than CureVac, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CureVac NV Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CureVac NV's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CureVac NV, and traders can use it to determine the average amount a CureVac NV's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1241
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CVAC |
Estimated Market Risk
| 3.13 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.39 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CureVac NV is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CureVac NV by adding CureVac NV to a well-diversified portfolio.
CureVac NV Fundamentals Growth
CureVac Stock prices reflect investors' perceptions of the future prospects and financial health of CureVac NV, and CureVac NV fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CureVac Stock performance.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (4.94) % | ||||
| Current Valuation | 12.58 M | ||||
| Shares Outstanding | 224.34 M | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 8.48 X | ||||
| Revenue | 53.76 M | ||||
| Gross Profit | (91.55 M) | ||||
| EBITDA | (234.09 M) | ||||
| Net Income | (259.97 M) | ||||
| Cash And Equivalents | 540.87 M | ||||
| Cash Per Share | 2.85 X | ||||
| Total Debt | 41.82 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.61 X | ||||
| Book Value Per Share | 1.68 X | ||||
| Cash Flow From Operations | (267.89 M) | ||||
| Earnings Per Share | 0.50 X | ||||
| Market Capitalization | 558.6 M | ||||
| Total Asset | 788.25 M | ||||
| Retained Earnings | (1.57 B) | ||||
| Working Capital | 291.99 M | ||||
About CureVac NV Performance
By analyzing CureVac NV's fundamental ratios, stakeholders can gain valuable insights into CureVac NV's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CureVac NV has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CureVac NV has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 72.79 | 132.40 | |
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.46) | (0.48) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (0.50) | (0.53) |
Things to note about CureVac NV performance evaluation
Checking the ongoing alerts about CureVac NV for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CureVac NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CureVac NV generated a negative expected return over the last 90 days | |
| CureVac NV has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 53.76 M. Net Loss for the year was (259.97 M) with loss before overhead, payroll, taxes, and interest of (91.55 M). | |
| CureVac NV currently holds about 540.87 M in cash with (267.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| CureVac NV has a poor financial position based on the latest SEC disclosures | |
| Roughly 45.0% of the company shares are held by company insiders | |
| Latest headline from zacks.com: Is the Options Market Predicting a Spike in CureVac Stock |
- Analyzing CureVac NV's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CureVac NV's stock is overvalued or undervalued compared to its peers.
- Examining CureVac NV's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CureVac NV's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CureVac NV's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CureVac NV's stock. These opinions can provide insight into CureVac NV's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |